Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Guinness China Sharukh Malik, Edmund Harriss | “Shenzhen Mindray Bio-Medical (-25.8%) is a Chinese medical device manufacturer. The shares were held back by continued weakness in the domestic market, where tighter hospital budgets and delayed procurement remained a drag on demand. This was partly offset by strong overseas growth, particularly in Europe and developing markets, as Mindray continued to expand its presence among hospitals. The company also continued to gain market share in domestic in-vitro diagnostics, supported by the installation of its laboratory-automation systems and a broad product offering, while newer businesses such as minimally invasive surgery, interventional products and animal health maintained strong momentum. First-quarter revenue rose 1%, while net income declined 11%, partly reflecting foreign-exchange headwinds. Looking ahead, international expansion, further market share gains and growth in emerging businesses should support a gradual recovery, although domestic hospital funding constraints and policy-driven pricing pressure remain headwinds.” | NEUTRAL | Q2 2026 Jul 22, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
